2020
Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally LM, Sherr JL, Van Name MA, Patel AD, Tamborlane WV. Pharmacologic treatment options for type 1 diabetes: what’s new? Expert Review Of Clinical Pharmacology 2019, 12: 471-479. PMID: 30892094, PMCID: PMC6488361, DOI: 10.1080/17512433.2019.1597705.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAdjunctive therapyType 1 diabetesInsulin analoguesMimic physiologic insulin secretionGLP-1 receptor agonistsPhysiologic insulin secretionPharmacologic treatment optionsDPP-4 inhibitorsType 2 diabetesVariety of insulinBiosynthetic human insulinPotential adverse effectsSGLT1/2 inhibitorsBasal insulinPharmacologic treatmentTreatment optionsReceptor agonistInsulin secretionSGLT-2Abnormal physiologyProlonged durationTherapyDiabetesInsulinNovel drugs
2015
The past, present, and future of basal insulins
Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes/Metabolism Research And Reviews 2015, 32: 478-496. PMID: 26509843, DOI: 10.1002/dmrr.2763.Peer-Reviewed Original ResearchConceptsInsulin glargine 100Basal insulinGlargine 100Glycemic controlUnits/mLNew insulin glargine 300Neutral protamine Hagedorn (NPH) insulinBasal insulin peglisproNew insulin productsSimilar glycemic controlGood glycemic controlInsulin glargine 300Type 2 diabetesDuration of actionInsulin delivery techniquesGlargine 300Insulin detemirInsulin therapyInsulin degludecNew insulinsPharmacodynamic profileInsulin secretionPharmacodynamic propertiesPrandial increaseFundamental therapyC‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistryCGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes
Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R, Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network (DirecNet) and Type 1 Diabetes TrialNet Study Groups. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia 2015, 58: 1167-1174. PMID: 25773405, PMCID: PMC4416994, DOI: 10.1007/s00125-015-3559-y.Peer-Reviewed Original ResearchConceptsC-peptide levelsType 1 diabetesHigher C-peptide levelsC-peptideGlucose levelsTime pointsGlucose valuesMixed meal tolerance testAims/hypothesisThe aimCGM glucose levelsC-peptide responseWeeks of diagnosisOnset of diabetesLower glucose variabilityConclusions/interpretationInMethodsA secondary analysisSensor glucose levelsCGM glucose valuesAdditional time pointsHypothesisThe aimGlucose variabilityTolerance testContinuous glucose monitoring dataInsulin secretionCGM metrics
2012
Insulin Therapy in Children and Adolescents
Tamborlane WV, Sikes KA. Insulin Therapy in Children and Adolescents. Endocrinology And Metabolism Clinics Of North America 2012, 41: 145-160. PMID: 22575411, DOI: 10.1016/j.ecl.2012.01.002.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous insulin infusionInsulin therapyBasal-bolus therapyMainstay of treatmentInsulin replacement therapyType 2 diabetesType 1 diabetesDaily injectionsReplacement therapyAnalogue insulinInsulin infusionInsulin secretionBiosynthetic humanTherapyInsulin formulationsNormal patternDiabetesTreatmentChildrenAdolescentsInfusionAimMainstayInsulin
1995
Central adiposity and its metabolic correlates in obese adolescent girls
Caprio S, Hyman LD, Limb C, McCarthy S, Lange R, Sherwin RS, Shulman G, Tamborlane WV. Central adiposity and its metabolic correlates in obese adolescent girls. American Journal Of Physiology 1995, 269: e118-e126. PMID: 7631766, DOI: 10.1152/ajpendo.1995.269.1.e118.Peer-Reviewed Original ResearchConceptsObese adolescent girlsObese girlsInsulin secretionInsulin actionSubcutaneous abdominal fat depotsFree fatty acid levelsGlucose-stimulated insulin responseHip circumference ratioEuglycemic insulin clampHyperglycemic clamp techniqueBasal insulin secretionAbdominal fat depotsAdolescent girlsHepatic glucose productionFatty acid levelsMagnetic resonance imagingLean womenCentral adiposityInsulin dosesVisceral fatInsulin clampInsulin resistanceNonobese girlsGlucose disposalInsulin infusion
1992
Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism
Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acid metabolism. American Journal Of Physiology 1992, 262: e130-e133. PMID: 1733244, DOI: 10.1152/ajpendo.1992.262.1.e130.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIGF-I levelsGrowth factor IInsulin secretionTotal IGF-I levelsFree IGF-I levelsAcid metabolismRecombinant human insulin-like growth factor IFactor IAmino acid metabolismFree fatty acid metabolismHealthy nonobese subjectsHuman insulin-like growth factor IHepatic glucose productionBranched-chain amino acidsExogenous glucose infusionFatty acid metabolismGlucagon levelsInsulin levelsNonobese subjectsContinuous infusionConcomitant inhibitory effectTwo- to threefold increaseC-peptideGlucose infusion
1988
Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion
Merkel PA, Simonson DC, Amiel SA, Plewe G, Sherwin RS, Pearson HA, Tamborlane WV. Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion. New England Journal Of Medicine 1988, 318: 809-814. PMID: 3281000, DOI: 10.1056/nejm198803313181303.Peer-Reviewed Original ResearchConceptsInsulin resistanceInsulin levelsThalassemia majorInsulin-stimulated glucose metabolismC-peptide levelsDevelopment of diabetesOral glucose administrationPlasma insulin levelsHypertransfusion therapyPubertal patientsPrepubertal patientsDiabetes mellitusGlucose toleranceInsulin deficiencyPubertal childrenGlucose administrationInsulin secretionIron overloadPrepubertal childrenChelation therapyPubertal subjectsGlucose metabolismBeta cellsHyperglycemic stimulusPatients